To include your compound in the COVID-19 Resource Center, submit it here.

Tofacitinib: Additional Phase III data

Additional data from the double-blind, international Phase III ORAL Sync (1046) trial in 792 RA patients who had an inadequate response to a DMARD showed that twice-daily 5 and 10 mg oral tofacitinib led to ACR20 response rates at 6 months of 52.7% and 58.3%,

Read the full 453 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE